US2018334435A1PendingUtilityA1
6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
Est. expiryFeb 6, 2034(~7.5 yrs left)· nominal 20-yr term from priority
Inventors:Andrew BogdanMarlon D. CowartDavid A. DegoeyTammie K. JinkersonJohn R. KoenigMichael E. KortBo LiuMark A. MatulenkoDerek W. NelsonMeena V. PatelHillary PeltierMarc J. ScanioBrian D. Wakefield
A61P 43/00A61P 25/04A61P 25/06A61P 29/00A61P 25/02A61P 29/02C07D 487/04C07D 405/12C07D 471/04C07D 405/14A61K 31/498C07D 215/48C07D 417/12C07D 401/12C07D 401/14C07D 417/14C07D 487/08A61P 1/02A61K 31/4709C07D 409/12A61K 31/5377C07D 409/14A61P 25/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Claims
exact text as granted — not AI-modified1 - 26 . (canceled)
27 . A method of treating a condition or disorder modulated by the voltage-gated sodium channels Na v 1.7 and/or Na v 1.8 in a mammal comprising administering an effective amount of [(3R)-3-fluoropyrrolidin-1-yl](6-{[5-(trifluoromethyl)pyridin-2-yl]oxy}quinolin-2-yl)methanone, or a pharmaceutically acceptable salt thereof.
28 . (canceled)Join the waitlist — get patent alerts
Track US2018334435A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.